Big Pharma's vaccine land grab

Overview

Sanofi dropped $2.2 billion on December 24, 2025 to acquire Dynavax, a California biotech with a two-dose hepatitis B vaccine and a shingles vaccine in development. The 39% premium signals desperation in a market projected to hit $37.2 billion by 2033, driven by aging populations; the deal is expected to close in Q1 2026 pending Hart-Scott-Rodino antitrust clearance.[1] By 2050, 2.1 billion people will be over 60, triple the population over 80.

GSK controls 94% of the $4.9 billion shingles market with Shingrix. Curevo raised $110 million in March 2025 and launched Phase 2 trials of amezosvatein, a shingles vaccine showing zero severe side effects versus Shingrix's debilitating reactogenicity. Merck paid $9.2 billion for Cidara's flu antiviral.

The Sanofi-Dynavax deal is the latest in a consolidation wave in the vaccine industry, with new competitors emerging. PwC's 2026 M&A outlook identifies the deal as emblematic of pharma's strategy to fill pipeline gaps and reposition portfolios against patent cliffs.[3] Big Pharma sees vaccine portfolios as insurance against patent cliffs and is buying every promising asset before rivals do.

Play on this story Voices Debate Who Said What? Predict

Key Indicators

$2.2B

Sanofi-Dynavax Deal Value

39% premium over prior close, doubling Sanofi's adult vaccine capabilities

46%

HEPLISAV-B Market Share

Dynavax's hep B vaccine now captures nearly half the U.S. market

$37.2B

Adult Vaccine Market by 2033

Up from $21.8B in 2024, fueled by aging demographics and immunosenescence

2.1B

Global Population 60+ by 2050

Nearly doubling from 1B in 2020, with 80+ cohort tripling to 426M

94%

GSK's Shingrix Dominance

Near-monopoly on $4.9B shingles market creates acquisition urgency

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

People Involved

Ryan Spencer

Leading company through $2.2B acquisition by Sanofi

Thomas Triomphe

Leading Sanofi's vaccine expansion strategy

Organizations Involved

Sanofi

Pharmaceutical Company

Acquiring Dynavax to strengthen adult vaccine portfolio

French pharma giant racing to build a €10 billion vaccine business by 2030 through aggressive M&A.

Dynavax Technologies

Biopharmaceutical company

Being acquired by Sanofi for $2.2 billion

California biotech that built a hepatitis B vaccine franchise and supplies adjuvants to vaccine makers globally.

GSK (GlaxoSmithKline)

Multinational pharmaceutical company

Market leader in adult vaccines, defending shingles monopoly

British pharma giant controlling 94% of the shingles vaccine market with Shingrix, setting the competitive bar Sanofi aims to challenge.

Curevo Vaccine

Biopharmaceutical company

Developing amezosvatein shingles vaccine with superior tolerability profile, Phase 2 extension ongoing

Biotech developing next-generation shingles vaccine targeting GSK's near-monopoly through superior tolerability.

Merck & Co.

Pharmaceutical Company

Expanding infectious disease portfolio through $9.2B Cidara acquisition

Pharmaceutical giant pivoting toward respiratory vaccines and antivirals as traditional small-molecule drugs face patent cliffs.

Timeline

Curevo Enrolls First Patients in Phase 2 Extension
Clinical Development

Phase 2 extension trial targeting 640 adults over age 70, head-to-head versus Shingrix, aiming to validate superior tolerability profile in oldest patients.
June 1st, 2025
Curevo Raises $110M for Shingles Vaccine
Financing

Series B round led by Medicxi with participation from OrbiMed, Sanofi Ventures, and others to advance amezosvatein through Phase 2 extension and prepare for Phase 3 pivotal trials.
March 17th, 2025
Curevo Reports Sustained Amezosvatein Immunogenicity
Clinical Development

Updated Phase 2 data shows amezosvatein antibody levels remained non-inferior to Shingrix one year after second dose, with zero Grade 3 side effects vs 19.1% Grade 2+ systemic reactions for Shingrix.
January 12th, 2025
Merck Acquires Cidara for $9.2 Billion
Acquisition

Merck pays $221.50/share for Cidara Therapeutics to gain CD388, a late-stage flu antiviral candidate positioning as universal alternative to traditional flu vaccines.
January 1st, 2025
Sanofi Announces Dynavax Acquisition
Acquisition

Sanofi agrees to acquire Dynavax for $15.50/share cash ($2.2B total), adding HEPLISAV-B and shingles candidate to portfolio. Stock surges 39%.
December 24th, 2024 • 6:15 AM
HEPLISAV-B Achieves Record Revenue
Commercial Milestone

Dynavax announces preliminary Q4 2024 results: HEPLISAV-B achieved record annual revenue of $268.4 million, reflecting 26% year-over-year growth.
December 1st, 2024
GSK Reduces China Shingrix Deliveries
Market Development

GSK extends Zhifei partnership to 11 years but significantly reduces planned deliveries—21.6 billion yuan over 2024-2029 vs original 20.6 billion yuan over just 2024-2026, signaling demand concerns.
December 1st, 2024
HEPLISAV-B Hits 46% Market Share
Commercial Milestone

Dynavax reports HEPLISAV-B captured 46% of U.S. hepatitis B vaccine market in Q3, up from 44% in 2023.
November 1st, 2024
Dynavax Presents Z-1018 Data at IDWeek
Clinical Development

Dynavax presents detailed Phase 1/2 data at IDWeek 2025 conference and announces initiation of Part 2 trial in adults 70+ years old.
October 1st, 2024
BioNTech Acquires CureVac
Acquisition

BioNTech announces $1.25 billion all-stock acquisition of CureVac, consolidating mRNA vaccine development capabilities.
September 1st, 2024
Z-1018 Phase 1/2 Shows Superior Tolerability
Clinical Development

Dynavax reports positive results: Z-1018 demonstrated comparable immunogenicity to Shingrix with significantly fewer side effects—12.5% vs 52.6% reported severe local reactions, 27.5% vs 63.2% severe systemic reactions.
August 1st, 2024
GSK-CureVac $1.4B mRNA Deal
Deal

GSK enters $1.4 billion licensing agreement with CureVac for next-generation mRNA vaccines targeting flu, COVID-19, and avian flu.
July 1st, 2024
Dynavax Begins Shingles Vaccine Trial
Clinical Development

Dynavax doses first patient in Phase 1/2 trial of Z-1018 shingles vaccine candidate.
June 10th, 2024
Novavax-Sanofi COVID Vaccine Partnership
Deal

Sanofi and Novavax announce co-exclusive licensing for COVID-19 vaccine and combination shots, signaling Sanofi's vaccine expansion strategy.
May 1st, 2024

Scenarios

Predict which scenario wins. Contrarian picks score more — points lock in when the scenario resolves.

Predictions leaderboard

Sanofi Challenges GSK's Shingles Monopoly by 2030

If Dynavax's Z-1018 shingles vaccine passes Phase 3 trials and demonstrates fewer side effects than Shingrix (which sidelines 1 in 6 patients), Sanofi could capture 20-30% of a market projected to hit $12.9 billion by 2034. The adjuvant technology underlying both HEPLISAV-B and Z-1018 suggests Dynavax knows how to stimulate immune response without the reactogenicity plaguing Shingrix. Success here would validate Sanofi's adult vaccine strategy and pressure GSK to cut pricing or improve formulations.

Discussed by: Industry analysts at FinancialContent, vaccine market forecasters

Consensus —

Acquisition Fails to Move Market Share, Asset Write-Down by 2027

HEPLISAV-B's 46% market share may represent its ceiling—physician adoption has plateaued despite the two-dose advantage. The shingles candidate remains years from approval, and Pfizer/BioNTech's mRNA shingles vaccine could leapfrog Dynavax's adjuvanted approach. If Z-1018 fails in Phase 3 or mRNA vaccines prove superior, Sanofi overpaid for a single-product company with limited growth runway. Shareholders already signal disappointment that the $2.2 billion price undervalues the pipeline, suggesting both sides may end up dissatisfied.

Discussed by: Seeking Alpha analysts questioning the premium paid

Consensus —

Consolidation Triggers Regulatory Antitrust Review

As Big Pharma acquires vaccine specialists, concentration intensifies in markets critical to public health. GSK controls shingles, Sanofi would control nearly half the hepatitis B market post-acquisition, and mRNA platforms are consolidating around Pfizer/BioNTech and Moderna. If regulators determine this wave threatens competition or vaccine affordability, the FTC could block the Dynavax deal or impose divestitures. More likely: increased scrutiny on future vaccine M&A, forcing companies to justify acquisitions on innovation grounds rather than market elimination.

Discussed by: Healthcare policy watchers, FTC antitrust observers

Consensus —

Z-1018 Captures Premium Pricing Through Tolerability Advantage

The August 2024 Phase 1/2 data showed Z-1018 delivers comparable immune response with 4x fewer severe side effects than Shingrix. If this profile holds in Phase 3, Sanofi could position Z-1018 as a premium alternative for patients who delayed vaccination due to Shingrix's notorious reactogenicity. With 1 in 6 Shingrix recipients experiencing debilitating side effects, a better-tolerated option could command pricing power even without superiority claims, potentially capturing 15-25% market share by avoiding direct efficacy competition while addressing a real patient need.

Discussed by: Seeking Alpha analysts, vaccine market strategists

Consensus —

Curevo's Amezosvatein Captures 30% of Shingles Market by 2028

Curevo's March 2025 funding and Phase 2 extension trial position amezosvatein as a best-in-class shingles vaccine with superior tolerability. If Phase 2 extension replicates the zero severe side effects seen in initial trials—versus Shingrix's 19% severe systemic reaction rate—physicians may preferentially prescribe amezosvatein for patients over 70, the fastest-growing demographic. This would fragment the market three ways: GSK defending Shingrix's efficacy advantage, Sanofi offering Z-1018 as mid-tier option, and Curevo capturing the tolerability-sensitive segment willing to pay premium pricing to avoid debilitating side effects.

Discussed by: Biotech investors at Medicxi, OrbiMed; vaccine market analysts

Consensus —

2033 Adult Vaccine Market Undershoots Projections Due to mRNA Disruption

The $37.2B market projection assumes traditional adjuvanted vaccines continue dominating adult immunization. But mRNA platforms—proven at scale during COVID—may leapfrog protein subunit vaccines in shingles, flu, and RSV markets. AIM Vaccine received FDA clinical approval for mRNA shingles vaccine in March 2025; Pfizer/BioNTech have undisclosed mRNA shingles programs. If mRNA vaccines demonstrate superior efficacy with faster manufacturing and lower cost structures, traditional adjuvant-based platforms underlying both Dynavax and Curevo pipelines could become stranded assets, making Sanofi's $2.2B bet a value trap rather than strategic insurance.

Discussed by: Healthcare forecasters, mRNA platform developers

Consensus —

Historical Context

Pfizer's Acquisition of Wyeth (2009)

2009

What Happened

During the financial crisis, Pfizer paid $68 billion for Wyeth, largely to acquire its vaccine portfolio including Prevnar (pneumococcal). The deal gave Pfizer critical mass in vaccines at a time when primary-care blockbusters faced patent cliffs and pricing pressure.

Outcome

Short Term

Prevnar became one of Pfizer's top revenue generators, validating the vaccine bet.

Long Term

Established the playbook: acquire vaccine assets during market uncertainty to diversify from small-molecule drugs facing patent expiration and political pricing pressure.

Why It's Relevant Today

Sanofi is following the same script—facing patent cliffs, it's buying commercial vaccine products and pipeline candidates to sustain growth as traditional drugs lose exclusivity.

GSK's Shingrix Launch Disrupts Market (2017)

2017-present

What Happened

GSK launched Shingrix with >90% efficacy, instantly obsoleting Merck's live-virus Zostavax. Within three years, Shingrix captured 94% market share and generated £3+ billion annually, demonstrating how clinical superiority can create near-monopolies in adult vaccines.

Outcome

Short Term

Merck withdrew Zostavax from the U.S. market by 2020, ceding the field entirely to GSK.

Long Term

Every major pharma launched shingles programs to challenge GSK, including Pfizer/BioNTech (mRNA), Curevo (reduced side effects), and now Sanofi via Dynavax acquisition.

Why It's Relevant Today

The Dynavax shingles candidate represents Sanofi's attempt to replicate GSK's playbook—use superior technology (CpG 1018 adjuvant) to differentiate and capture market share from an entrenched incumbent.

COVID-19 Vaccine mRNA Gold Rush (2020-2021)

2020-2021

What Happened

Pfizer/BioNTech and Moderna generated $75+ billion in COVID vaccine revenue, proving mRNA technology could produce safe, effective vaccines at unprecedented speed. Traditional vaccine makers like Sanofi watched from the sidelines as biotech upstarts captured windfall profits.

Outcome

Short Term

Big Pharma launched acquisition spree to acquire mRNA capabilities—Sanofi bought Translate Bio ($3.2B), GSK partnered with CureVac ($1.4B), BioNTech acquired CureVac ($1.25B).

Long Term

Vaccine development bifurcated into mRNA platforms (faster, flexible) and traditional approaches (adjuvants, recombinant proteins), with companies hedging by investing in both.

Why It's Relevant Today

The Dynavax deal shows Sanofi hasn't fully committed to mRNA—it's diversifying with proven adjuvant technology, betting both platforms will coexist in a market where speed, efficacy, and tolerability all matter.